![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1348457
¼¼°èÀÇ ½ºÅéÄÛ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®(2024-2030³â) - MedCoreStopcock Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore |
2023³â ¼¼°èÀÇ ½ºÅéÄÛ(Stopcock) ½ÃÀå ±Ô¸ð´Â 1¾ï 7,510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³â 1¾ï 6,570¸¸ ´Þ·¯¿¡ ºñÇØ 5.7% Áõ°¡Çß½À´Ï´Ù. ÇâÈÄ ¿¹Ãø¿¡¼ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.9%·Î ±Ã±ØÀûÀ¸·Î 2¾ï 4,550¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÇöÀç ¼¼°èÀÇ ½ºÅéÄÛ ½ÃÀåÀº Becton Dickinson(BD)°ú B. BraunÀÌ µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
½ºÅéÄÛÀº ½ÃÀå¿¡¼ ´ëü ±â¼ú·Î ÀÎÁ¤¹Þ°í ÀÖ´Â »õ·Î¿î ´Ïµé¸®½º Ä¿³ØÅÍ¿Í °æÀïÇϰí ÀÖ½À´Ï´Ù. ¹Ù´Ã ¾ø´Â Ä¿³ØÅÍ´Â °¨¿° °ü¸® °³¼±, ¼ö¾× ³¶ºñ °¨¼Ò, ¼ö¾× °ü¸®ÀÇ Á¤¹Ðµµ Çâ»ó µî ´Ù¾çÇÑ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¿³ØÅÍ´Â Á¡Á¡ ´õ ½±°Ô Á¢±ÙÇϰí äÅÃÇÒ ¼ö ÀÖ°Ô µÇ¸é¼ ±âÁ¸ ½ºÅéÄÛ ½ÃÀå¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¹Ù´Ã ¾ø´Â Ä¿³ØÅͰ¡ °è¼Ó Àα⸦ ¾òÀ¸¸é¼ ƯÁ¤ ¾ÖÇø®ÄÉÀ̼ǰú ÀÇ·á ȯ°æ¿¡¼ ±âÁ¸ ½ºÅéÄÛÀ» Á¡Â÷ ´ëüÇϰí ÀÖ½À´Ï´Ù.
2023³â, Becton Dickinson(BD)Àº ¼¼°èÀÇ ½ºÅéÄÛ ½ÃÀå¿¡¼ ºÎµ¿ÀÇ ¼±µÎ¿¡ ¼¼ »ê¾÷ÀÇ Áö¹èÀû ÁöÀ§¸¦ ±»Çû½À´Ï´Ù. BD´Â µÎ °¡Áö Áß¿äÇÑ Á¦Ç°À» Á¦°øÇÕ´Ï´Ù. BDÀÇ ¾ÐµµÀûÀÎ ¿µÇâ·ÂÀº ½ÃÀå Á¡À¯À² 2À§ÀÎ ºÏ¹Ì¿Í ¼À¯·´»Ó¸¸ ¾Æ´Ï¶ó ¼¼°èÀÇ ¿©·¯ Áö¿ª ½ÃÀå¿¡µµ À̸£°í ÀÖ½À´Ï´Ù.
°°Àº ÇØ, B. BraunÀº Àü ¼¼°è ½ºÅéÄÛ ºÐ¾ß¿¡¼ µÎ ¹øÂ°·Î ¿µÇâ·Â ÀÖ´Â °æÀï¾÷ü·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ÀÎÇ»Àü ÆßÇÁ Á¦Á¶¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ¸·Î À¯¸íÇÑ B. BraunÀº ½ºÅéÄÛ ÀåÄ¡¸¦ ´Ù¸¥ ÀÇ·á Àåºñ¿Í ÇÔ²² ¹øµé·Î Á¦°øÇÏ´Â Â÷º°ÈµÈ Á¢±Ù ¹æ½ÄÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº º´¿ø¿¡¼´Â ´ëºÎºÐÀÇ ¼ö¾× Á¦Ç°À» ´ÜÀÏ Á¦Á¶¾÷ü¿¡¼ Á¶´ÞÇÏ´Â Æ÷°ýÀûÀÎ ¼Ò½Ì ¹æ½ÄÀ» ¼±È£ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àû ÀÌÁ¡Àº ƯÈ÷ ´Ù¾çÇÑ ÀÇ·á ±â±â¿¡¼ Áö¼ÓÀûÀ¸·Î µÎ°¢À» ³ªÅ¸³»°í ÀÖ´Â ¼À¯·´ÀÇ ½ºÅéÄÛ ½ÃÀå¿¡¼ B. BraunÀÇ ÀÔÁö¸¦ Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù.
¼¼°èÀÇ ½ºÅéÄÛ(Stopcock) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä/ºÎ¹®º°¡¤Áö¿ªº° µ¿Çâ/°æÀï ±¸µµ µî Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
In 2023, the worldwide stopcock market achieved a total valuation of $175.1 million, reflecting a 5.7% increase compared to the $165.7 million recorded in 2022. Projections for the upcoming period suggest a sustained growth trajectory, with a compound annual growth rate (CAGR) of 4.9%, ultimately reaching $245.5 million. Presently, the global stopcock market is under the dominance of Becton Dickinson (BD) and B. Braun.
Our comprehensive medical market research involved a thorough analysis of more than 20 stopcock companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
Stopcocks are encountering competition from emerging needleless connectors, which are gaining recognition as alternative technologies in the market. Needleless connectors offer various advantages, such as improved infection control, reduced fluid wastage, and enhanced precision in fluid management. These connectors are increasingly becoming more accessible and adopted, influencing traditional segments of the stopcock market. As needleless connectors continue to gain popularity, they are gradually displacing conventional stopcocks in specific applications and healthcare settings.
In 2023, Becton Dickinson (BD) emerged as the undisputed leader in the global stopcock market, solidifying its dominant position in the industry. BD proudly offers two significant offerings: the Alaris® lipid-resistant, 3-way stopcock, and an alternative latex- and PVC-free version of this essential medical device. BD's commanding influence extends not only to North America and Western Europe, where it holds the second-largest market share, but also to numerous regional markets across the globe.
During the same year, B. Braun secured its position as the second most influential competitor in the global stopcock arena. Renowned for its expertise in infusion pump manufacturing, B. Braun adopts a distinctive approach by bundling its stopcock devices with other medical equipment. Many hospitals prefer a comprehensive sourcing approach, choosing to procure the majority of their infusion products from a single manufacturer. This strategic advantage significantly enhances B. Braun's standing in the stopcock market, particularly in Western Europe, where it consistently excels across a diverse range of medical devices.
The lower tiers of the global stopcock market landscape are predominantly occupied by smaller, localized competitors. These agile players specialize in producing straightforward, cost-effective products tailored for hospital use. Nevertheless, their market share remains modest compared to industry giants capable of bundling stopcock sales with a comprehensive suite of infusion therapy products. Notably, companies like B. Braun and Becton Dickinson, among others, reign supreme in this category, leveraging their extensive product portfolios to maintain a dominant presence.